This article deals with metabolic-immune processes at rest and under stress conditions, which, in turn, results in the development of immune-dependent and immune-associated disorders. The article analyzes study results and conclusions of various literature sources and experimental data in healthy individuals and patients suffering from non-specific inflammatory lung diseases; purulent-inflammatory diseases and their combinations, primary and secondary progressive multiple sclerosis in the acute stage and remission. Research studies investigated the impact of the type, stage, combination of diseases on the parameters of the immunologic and metabolic statuses, as well as their correlations. The authors also analyzed metabolic effects of immunomodulators. Based on the analysis of the literature and own clinical and experimental data, the authors identified the ability of metabolic factors to regulate immunological processes. A correlative analysis of examination results of the patients with various diseases helped detect the unity of the immune-metabolic mechanisms of pathology. The data on the therapeutic effect of various modulators through differentiated biochemical chains and vice versa -the metabolic effect through immunological mechanisms -were analyzed in the study. Thus, one can testify that there is the phenomenon of a mediated effect of some immunocorrectors on the reactivity through metabolic chains. The fact that a number of modulators and metabolics can simultaneously affect the biochemical and immunological parameters of patients proved the above phenomenon. There was revealed a significant correlation interaction of the immune-metabolic parameters with various types of purulent-inflammatory diseases, which proves the formation of a single mechanism of pathology. Keywordsimmunomodulators, immunotropic effect, immuno-metabolic parameters, metabolics.Note: parameters of the standard formulas of the immune system disorders and metabolic disorders included in the key risk factors are given in bold; GP -glutathione reductase, GR -glutathione reductase, CIC -circulating immune complexes, VE -vitamin E, NK -natural killers, MDA -malonic dialdehyde, PPMS -primary progressive forms, SPMS -secondary progressive forms.

Introduction: Inflammatory diseases of the female genital organs rank among the leading ones in the total number of women of reproductive age. This results from a decrease in immunity, early sexual activity, neglect of personal hygiene, abortions, birth complications, etc. Materials and Methods: The study included 100 patients suffering from exacerbated chronic salpingo-oophoritis and its combination with bacterial vaginosis. In the study, all the patients were randomly divided into five groups, with 20 patients each. The patients were treated in the prescribed regimens and doses, according to the standards of specialized medical care. An immunomodulator immunomax and an antioxidant hypoxene were chosen as additional treatment options. Clinical and laboratory parameters were measured in all the patients before and after the treatment. The effectiveness of the treatment was evaluated 10-14 days later. In 18 people, the procedure was repeated after 2-3 months. Results and Discussion: It was found that the standard therapy to treat exacerbated chronic salpingo-oophoritis reduced inflammatory manifestations after 10-14 days; however, the risk of complications and relapse of the disease remained. Immunomax provided satisfactory second-order normalization of the immunological and metabolic parameters, ultimate normalization of pro-inflammatory parameters and absolutely no positive effect on the clinical parameters in patients with chronic salpingo-oophoritis in the acute stage, when compared with the standard treatment. A complex therapy of salpingo-oophoritis with bacterial vaginosis by means of immunomax and hypoxene aimed to normalize most clinical and laboratory parameters was absolutely positive; a moderate level of parameters was revealed only in cellular-humoral immunity. Conclusion: After 10-14 days, the standard treatment of patients resulted in normalization of the pro-inflammatory and immunological parameters, rather than the clinical and metabolic parameters. The administration of immunomax contributed to the correction of metabolic, immunological and pro-inflammatory markers, and the complex administration of an immunomodulator with an antioxidant favorably affected all the laboratory parameters.